You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemocapril
Accession NumberDB08836
TypeSmall Molecule
GroupsExperimental, Investigational
DescriptionTemocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
Structure
Thumb
Synonyms
Temocaprilum
External Identifiers
  • CS-622
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcecolSankyo
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Temocapril hydrochloride
110221-44-8
Thumb
  • InChI Key: XDDQNOKKZKHBIX-ASBZXGSUSA-N
  • Monoisotopic Mass: 512.120641135
  • Average Mass: 513.07
DBSALT000171
Categories
UNII18IZ008EU6
CAS number111902-57-9
WeightAverage: 476.609
Monoisotopic: 476.143963396
Chemical FormulaC23H28N2O5S2
InChI KeyFIQOFIRCTOWDOW-BJLQDIEVSA-N
InChI
InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
IUPAC Name
2-[(2S,6R)-6-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl]acetic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CS[C@@H](CN(CC(O)=O)C1=O)C1=CC=CS1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Phenylpropylamine
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiophene
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Dialkylthioether
  • Thioether
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationTemocapril is an ACE inhibitor primarily indicated in the treatment of hypertension and congestive heart failure, diabetic nephropathy, and improvement of prognosis for coronary artery diseases (including acute myocardial infarction).
PharmacodynamicsTemocapril is a prodrug of its active metabolite (and diacid form) temocaprilat which contains a thiazepine ring. Temocaprilat has slightly higher potency than enalaprilat in ACE inhibition isolated from rabbit lung. ACE inhibitors exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.). When compared with other Angiotensin-converting Enzyme Inhibitors, temocapril's advantages include a rapid onset of action and what research suggests is tighter vascular ACE binding than enalaprilat.
Mechanism of actionNot Available
Related Articles
AbsorptionTemocapril is rapidly absorbed in the gastrointestinal tract and converted into the diacid (active) metabolite, which inhibits ACE in plasma.
Volume of distributionNot Available
Protein binding99.5%, including those with renal impairment.
MetabolismNot Available
Route of eliminationTemocapril is eliminated primarily through the liver and kidneys.
Half life13.1 hours in patients with normal liver function.
Clearance

19.4% urinary recovery.

ToxicityIn rats, whether or male or female, the LD50 values of temocapril were higher than 5000 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Temocapril Action PathwayDrug actionSMP00733
Temocapril Metabolism PathwayDrug metabolismSMP00732
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9707
Blood Brain Barrier-0.8501
Caco-2 permeable-0.6871
P-glycoprotein substrateSubstrate0.8016
P-glycoprotein inhibitor INon-inhibitor0.6373
P-glycoprotein inhibitor IINon-inhibitor0.9056
Renal organic cation transporterNon-inhibitor0.8744
CYP450 2C9 substrateNon-substrate0.6676
CYP450 2D6 substrateNon-substrate0.8686
CYP450 3A4 substrateSubstrate0.5082
CYP450 1A2 substrateNon-inhibitor0.7748
CYP450 2C9 inhibitorNon-inhibitor0.6996
CYP450 2D6 inhibitorNon-inhibitor0.8016
CYP450 2C19 inhibitorInhibitor0.5371
CYP450 3A4 inhibitorNon-inhibitor0.746
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7297
Ames testNon AMES toxic0.7962
CarcinogenicityNon-carcinogens0.8965
BiodegradationNot ready biodegradable0.9584
Rat acute toxicity2.3397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9862
hERG inhibition (predictor II)Inhibitor0.5523
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting pointdecomposes at 187Not Available
water solubility<1 mg/mLNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00342 mg/mLALOGPS
logP2.46ALOGPS
logP2.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)3.88ChemAxon
pKa (Strongest Basic)5.14ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity124.1 m3·mol-1ChemAxon
Polarizability49.28 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (163 KB)
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677 ]
  2. Furuta S, Kiyosawa K, Higuchi M, Kasahara H, Saito H, Shioya H, Oguchi H: Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol. 1993;44(4):383-5. [PubMed:8513851 ]
  3. Nakashima M, Yamamoto J, Shibata M, Uematsu T, Shinjo H, Akahori T, Shioya H, Sugiyama K, Kawahara Y: Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol. 1992;43(6):657-9. [PubMed:1493850 ]
  4. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A: Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovasc Drug Rev. 2004 Fall;22(3):189-98. [PubMed:15492767 ]
  5. Clearance of Temocapril and Enalapril during Haemodialysis Treatment [Link]
External Links
ATC CodesC09AA14
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (569 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Temocapril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Temocapril.
AcebutololAcebutolol may increase the hypotensive activities of Temocapril.
AceclofenacThe risk or severity of adverse effects can be increased when Temocapril is combined with Aceclofenac.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Temocapril.
AdapaleneThe risk or severity of adverse effects can be increased when Temocapril is combined with Adapalene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Temocapril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Temocapril.
AliskirenTemocapril may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Temocapril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temocapril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Temocapril.
AlprenololAlprenolol may increase the hypotensive activities of Temocapril.
AmbrisentanTemocapril may increase the hypotensive activities of Ambrisentan.
AmifostineTemocapril may increase the hypotensive activities of Amifostine.
AmilorideAmiloride may increase the hyperkalemic activities of Temocapril.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Temocapril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Temocapril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Temocapril.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Temocapril.
AmlodipineAmlodipine may increase the hypotensive activities of Temocapril.
AntipyrineThe risk or severity of adverse effects can be increased when Temocapril is combined with Antipyrine.
ApremilastThe risk or severity of adverse effects can be increased when Temocapril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Temocapril.
ArdeparinArdeparin may increase the hyperkalemic activities of Temocapril.
AtenololAtenolol may increase the hypotensive activities of Temocapril.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Temocapril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Temocapril.
AzapropazoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Azapropazone.
AzathioprineTemocapril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Temocapril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Temocapril.
BalsalazideThe risk or severity of adverse effects can be increased when Temocapril is combined with Balsalazide.
BemiparinBemiparin may increase the hyperkalemic activities of Temocapril.
BenazeprilBenazepril may increase the hypotensive activities of Temocapril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Temocapril.
BenmoxinBenmoxin may increase the hypotensive activities of Temocapril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Benoxaprofen.
BepridilBepridil may increase the hypotensive activities of Temocapril.
BetaxololBetaxolol may increase the hypotensive activities of Temocapril.
BethanidineBethanidine may increase the hypotensive activities of Temocapril.
BimatoprostBimatoprost may increase the hypotensive activities of Temocapril.
BisoprololBisoprolol may increase the hypotensive activities of Temocapril.
BoceprevirThe serum concentration of Temocapril can be decreased when it is combined with Boceprevir.
BosentanBosentan may increase the hypotensive activities of Temocapril.
BretyliumBretylium may increase the hypotensive activities of Temocapril.
BrimonidineTemocapril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Temocapril.
BromfenacThe risk or severity of adverse effects can be increased when Temocapril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Temocapril.
BumetanideBumetanide may increase the hypotensive activities of Temocapril.
BupranololBupranolol may increase the hypotensive activities of Temocapril.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Temocapril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Temocapril.
CandesartanCandesartan may increase the hypotensive activities of Temocapril.
CandoxatrilCandoxatril may increase the hypotensive activities of Temocapril.
CaptoprilCaptopril may increase the hypotensive activities of Temocapril.
CarbamazepineThe metabolism of Temocapril can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Temocapril.
CarprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Temocapril.
CarvedilolCarvedilol may increase the hypotensive activities of Temocapril.
CastanospermineThe risk or severity of adverse effects can be increased when Temocapril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Celecoxib.
CeliprololCeliprolol may increase the hypotensive activities of Temocapril.
CertoparinCertoparin may increase the hyperkalemic activities of Temocapril.
ChloroquineThe risk or severity of adverse effects can be increased when Temocapril is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Temocapril.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Temocapril.
CilazaprilCilazapril may increase the hypotensive activities of Temocapril.
CiprofloxacinTemocapril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Temocapril.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Temocapril.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Temocapril.
ClonidineClonidine may increase the hypotensive activities of Temocapril.
ClonixinThe risk or severity of adverse effects can be increased when Temocapril is combined with Clonixin.
CryptenamineCryptenamine may increase the hypotensive activities of Temocapril.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Temocapril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Temocapril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Temocapril.
CyclothiazideCyclothiazide may increase the hypotensive activities of Temocapril.
D-LimoneneThe risk or severity of adverse effects can be increased when Temocapril is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Temocapril.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Temocapril.
DebrisoquinDebrisoquin may increase the hypotensive activities of Temocapril.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Temocapril.
DeserpidineTemocapril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Temocapril.
DiazoxideDiazoxide may increase the hypotensive activities of Temocapril.
DiclofenacThe risk or severity of adverse effects can be increased when Temocapril is combined with Diclofenac.
DiflunisalThe risk or severity of adverse effects can be increased when Temocapril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Temocapril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Temocapril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Temocapril.
DiltiazemDiltiazem may increase the hypotensive activities of Temocapril.
DorzolamideDorzolamide may increase the hypotensive activities of Temocapril.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Temocapril.
DoxazosinDoxazosin may increase the hypotensive activities of Temocapril.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Temocapril.
DrospirenoneTemocapril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Droxicam.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Temocapril.
EfonidipineTemocapril may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Temocapril.
EnalaprilatTemocapril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Temocapril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Temocapril.
EpirizoleThe risk or severity of adverse effects can be increased when Temocapril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Temocapril.
EpoprostenolEpoprostenol may increase the hypotensive activities of Temocapril.
EprosartanEprosartan may increase the hypotensive activities of Temocapril.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Temocapril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Temocapril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Temocapril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Temocapril.
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Temocapril.
EtanerceptThe risk or severity of adverse effects can be increased when Temocapril is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Temocapril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Temocapril is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Temocapril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Temocapril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Temocapril.
exisulindThe risk or severity of adverse effects can be increased when Temocapril is combined with exisulind.
FelodipineFelodipine may increase the hypotensive activities of Temocapril.
FenbufenThe risk or severity of adverse effects can be increased when Temocapril is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Temocapril.
FenoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Temocapril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Temocapril is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Flurbiprofen.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Temocapril.
FosinoprilFosinopril may increase the hypotensive activities of Temocapril.
FurazolidoneFurazolidone may increase the hypotensive activities of Temocapril.
FurosemideFurosemide may increase the hypotensive activities of Temocapril.
GarlicThe serum concentration of Temocapril can be decreased when it is combined with Garlic.
GuanabenzGuanabenz may increase the hypotensive activities of Temocapril.
GuanadrelGuanadrel may increase the hypotensive activities of Temocapril.
GuanethidineGuanethidine may increase the hypotensive activities of Temocapril.
GuanfacineGuanfacine may increase the hypotensive activities of Temocapril.
HeparinHeparin may increase the hyperkalemic activities of Temocapril.
HexamethoniumTemocapril may increase the hypotensive activities of Hexamethonium.
HMPL-004The risk or severity of adverse effects can be increased when Temocapril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Temocapril.
HydralazineHydralazine may increase the hypotensive activities of Temocapril.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Temocapril.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Temocapril.
IbuprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Temocapril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Temocapril.
IcatibantThe risk or severity of adverse effects can be increased when Temocapril is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Temocapril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Temocapril.
IndapamideIndapamide may increase the hypotensive activities of Temocapril.
IndenololTemocapril may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Temocapril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Indoprofen.
IndoraminTemocapril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Temocapril.
IproniazidIproniazid may increase the hypotensive activities of Temocapril.
IrbesartanIrbesartan may increase the hypotensive activities of Temocapril.
IronThe risk or severity of adverse effects can be increased when Temocapril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Temocapril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Temocapril.
IsoxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Temocapril.
KebuzoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Temocapril is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Temocapril.
LacidipineTemocapril may increase the hypotensive activities of Lacidipine.
Lanthanum carbonateThe serum concentration of Temocapril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostLatanoprost may increase the hypotensive activities of Temocapril.
LeflunomideThe risk or severity of adverse effects can be increased when Temocapril is combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Temocapril.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Temocapril.
LisinoprilLisinopril may increase the hypotensive activities of Temocapril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Temocapril.
LofexidineLofexidine may increase the hypotensive activities of Temocapril.
LornoxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Temocapril.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Temocapril.
LoxoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Lumiracoxib.
MacitentanTemocapril may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Temocapril is combined with Magnesium salicylate.
ManidipineTemocapril may increase the hypotensive activities of Manidipine.
MasoprocolThe risk or severity of adverse effects can be increased when Temocapril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Temocapril.
MecamylamineMecamylamine may increase the hypotensive activities of Temocapril.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Temocapril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Temocapril.
MetamizoleThe risk or severity of adverse effects can be increased when Temocapril is combined with Metamizole.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Temocapril.
MethyldopaMethyldopa may increase the hypotensive activities of Temocapril.
Methylene blueMethylene blue may increase the hypotensive activities of Temocapril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Temocapril.
MetipranololMetipranolol may increase the hypotensive activities of Temocapril.
MetolazoneMetolazone may increase the hypotensive activities of Temocapril.
MetoprololMetoprolol may increase the hypotensive activities of Temocapril.
MibefradilMibefradil may increase the hypotensive activities of Temocapril.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Temocapril.
MinaprineMinaprine may increase the hypotensive activities of Temocapril.
MinoxidilMinoxidil may increase the hypotensive activities of Temocapril.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Temocapril.
MoclobemideMoclobemide may increase the hypotensive activities of Temocapril.
MoexiprilMoexipril may increase the hypotensive activities of Temocapril.
MolsidomineMolsidomine may increase the hypotensive activities of Temocapril.
MoxonidineTemocapril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Nabumetone.
NadololNadolol may increase the hypotensive activities of Temocapril.
NadroparinNadroparin may increase the hyperkalemic activities of Temocapril.
NaftifineThe risk or severity of adverse effects can be increased when Temocapril is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Temocapril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Temocapril is combined with NCX 4016.
NebivololNebivolol may increase the hypotensive activities of Temocapril.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Temocapril.
NepafenacThe risk or severity of adverse effects can be increased when Temocapril is combined with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Temocapril.
NicardipineNicardipine may increase the hypotensive activities of Temocapril.
NicorandilNicorandil may increase the hyperkalemic activities of Temocapril.
NicorandilTemocapril may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe risk or severity of adverse effects can be increased when Temocapril is combined with Niflumic Acid.
NiguldipineTemocapril may increase the hypotensive activities of Niguldipine.
NilvadipineNilvadipine may increase the hypotensive activities of Temocapril.
NimesulideThe risk or severity of adverse effects can be increased when Temocapril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Temocapril.
NisoldipineNisoldipine may increase the hypotensive activities of Temocapril.
NitrendipineNitrendipine may increase the hypotensive activities of Temocapril.
NitroprussideNitroprusside may increase the hypotensive activities of Temocapril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Temocapril.
ObinutuzumabTemocapril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Temocapril.
OlmesartanOlmesartan may increase the hypotensive activities of Temocapril.
OlopatadineThe risk or severity of adverse effects can be increased when Temocapril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Temocapril is combined with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Temocapril.
OrgoteinThe risk or severity of adverse effects can be increased when Temocapril is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Temocapril is combined with Oxaprozin.
OxprenololOxprenolol may increase the hypotensive activities of Temocapril.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Oxyphenbutazone.
ParecoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Parecoxib.
PargylinePargyline may increase the hypotensive activities of Temocapril.
ParnaparinParnaparin may increase the hyperkalemic activities of Temocapril.
PenbutololPenbutolol may increase the hypotensive activities of Temocapril.
PentoliniumPentolinium may increase the hypotensive activities of Temocapril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Temocapril.
PerindoprilPerindopril may increase the hypotensive activities of Temocapril.
PethidineThe risk or severity of adverse effects can be increased when Temocapril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Temocapril.
PheniprazinePheniprazine may increase the hypotensive activities of Temocapril.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Temocapril.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Temocapril.
PhentolaminePhentolamine may increase the hypotensive activities of Temocapril.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Temocapril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Temocapril.
PinacidilPinacidil may increase the hypotensive activities of Temocapril.
PindololPindolol may increase the hypotensive activities of Temocapril.
PiretanidePiretanide may increase the hypotensive activities of Temocapril.
PirfenidoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Temocapril.
PiroxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Temocapril.
PolythiazidePolythiazide may increase the hypotensive activities of Temocapril.
PrazosinPrazosin may increase the hypotensive activities of Temocapril.
PregabalinThe risk or severity of adverse effects can be increased when Temocapril is combined with Pregabalin.
PropacetamolThe risk or severity of adverse effects can be increased when Temocapril is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Temocapril.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Temocapril.
PTC299The risk or severity of adverse effects can be increased when Temocapril is combined with PTC299.
QuinaprilQuinapril may increase the hypotensive activities of Temocapril.
QuinethazoneQuinethazone may increase the hypotensive activities of Temocapril.
QuinineQuinine may increase the hypotensive activities of Temocapril.
RamiprilRamipril may increase the hypotensive activities of Temocapril.
RasagilineRasagiline may increase the hypotensive activities of Temocapril.
RemikirenRemikiren may increase the hypotensive activities of Temocapril.
RescinnamineTemocapril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Temocapril.
ResveratrolThe risk or severity of adverse effects can be increased when Temocapril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Temocapril.
RiociguatTemocapril may increase the hypotensive activities of Riociguat.
RituximabTemocapril may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Rofecoxib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Temocapril.
SacubitrilThe risk or severity of adverse effects can be increased when Temocapril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Temocapril.
SalicylamideThe risk or severity of adverse effects can be increased when Temocapril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Temocapril.
SalsalateThe risk or severity of adverse effects can be increased when Temocapril is combined with Salsalate.
SaprisartanSaprisartan may increase the hypotensive activities of Temocapril.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Temocapril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Temocapril.
SelegilineSelegiline may increase the hypotensive activities of Temocapril.
SelexipagTemocapril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Temocapril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Temocapril.
SildenafilSildenafil may increase the antihypertensive activities of Temocapril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Temocapril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Temocapril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Temocapril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Temocapril.
SitaxentanTemocapril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Temocapril is combined with Sodium aurothiomalate.
SpiraprilSpirapril may increase the hypotensive activities of Temocapril.
SpironolactoneSpironolactone may increase the hyperkalemic activities of Temocapril.
SRT501The risk or severity of adverse effects can be increased when Temocapril is combined with SRT501.
St. John's WortThe metabolism of Temocapril can be increased when combined with St. John&#39;s Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Temocapril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Temocapril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Temocapril.
TadalafilTadalafil may increase the antihypertensive activities of Temocapril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Temocapril.
TelmisartanTelmisartan may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Temocapril.
TenoxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Temocapril is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Temocapril is combined with Teriflunomide.
TerlipressinTerlipressin may increase the hypotensive activities of Temocapril.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Temocapril.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Temocapril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Tiaprofenic acid.
TiboloneTemocapril may increase the hypotensive activities of Tibolone.
TicrynafenTicrynafen may increase the hypotensive activities of Temocapril.
TimololTimolol may increase the hypotensive activities of Temocapril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Temocapril.
TipranavirThe serum concentration of Temocapril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Temocapril.
TolazolineTolazoline may increase the hypotensive activities of Temocapril.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Temocapril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Temocapril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Temocapril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Temocapril.
TorasemideTorasemide may increase the hypotensive activities of Temocapril.
TrandolaprilTrandolapril may increase the hypotensive activities of Temocapril.
TranilastThe risk or severity of adverse effects can be increased when Temocapril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Temocapril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Temocapril.
TravoprostTravoprost may increase the hypotensive activities of Temocapril.
TreprostinilTreprostinil may increase the hypotensive activities of Temocapril.
TriamtereneTriamterene may increase the hyperkalemic activities of Temocapril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Temocapril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Temocapril.
TrimazosinTemocapril may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Temocapril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Temocapril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Temocapril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Temocapril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Temocapril.
UnoprostoneUnoprostone may increase the hypotensive activities of Temocapril.
ValdecoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Temocapril.
VardenafilVardenafil may increase the antihypertensive activities of Temocapril.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temocapril.
XylometazolineXylometazoline may increase the hypotensive activities of Temocapril.
YohimbineYohimbine may decrease the antihypertensive activities of Temocapril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Temocapril.
ZileutonThe risk or severity of adverse effects can be increased when Temocapril is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Temocapril is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Furuta S, Kiyosawa K, Higuchi M, Kasahara H, Saito H, Shioya H, Oguchi H: Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol. 1993;44(4):383-5. [PubMed:8513851 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y: Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther. 1998 Oct;287(1):37-42. [PubMed:9765319 ]
Comments
comments powered by Disqus
Drug created on February 19, 2013 17:04 / Updated on August 17, 2016 12:24